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Abstract An antibody combining site generally involves the two
variable domains, VH from the heavy and VL from the light
chain. We expressed the individual VH domain of the mouse anti-
human ferritin monoclonal antibody F11. The loss of affinity was
not dramatic (Ka = 4.0U107 M31 versus 8.6U108 M31 for the
parent antibody) and comparable to that previously observed for
other VHs. However, the functional VH domain adopted a
partially structured state with a significant amount of distorted
secondary and compact yet greatly destabilized tertiary
structures, as demonstrated by spectroscopic and calorimetric
probes. These data provide the first description for a functional
antibody domain that meets all the criteria of a partially
structured state. ß 2002 Published by Elsevier Science B.V.
on behalf of the Federation of European Biochemical Societies.
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1. Introduction
The antigen-binding site in most antibody molecules is com-
posed of the non-covalently linked variable domains, VH
from the heavy chain and VL from the light chain. Recombi-
nant VH domains were recently reported to provide the spe-
ci¢c binding of the antigen in the absence of a partner VL
domain [1^3]. Accordingly, VH domains are considered prime
candidates for designing minimal recognition modules of im-
munotoxins, abzymes and other antibody-derived recombi-
nant proteins for therapeutic, diagnostic and industrial appli-
cations [4^6]. The discovery in Camelidae (camel and llama) of
structurally unique antibodies lacking the light chain and
therefore generating a high-a⁄nity binding site without the
assistance of VL domains [7] stimulated a rapid progress in
overcoming the two major drawbacks of VH domains, their
limited solubility and lower a⁄nity [2,3,6,8].
The VH domains were shown, by nuclear magnetic reso-
nance and X-ray crystallography, to adopt a typical immuno-
globulin fold with two adjacent disul¢de-linked L-sheets [9^
15]. These data suggest a completely folded conformation for
the VH domains. However, the antigen-binding site spans a
signi¢cant part of the VH molecule, and folding and stability
of antibody variable domains were shown to be dependent on
the structure of the complementarity-determining regions
(CDR loops) [16^19]. Therefore, one can presume distinct
correlates between folding, stability and a⁄nity in isolated
variable domains, and knowledge of these correlates is critical
for further engineering of single-domain recognition modules.
In support of this presumption, spectroscopically determined
thermal stability was shown to be high for two out of six
llama VHs [20], while for other previously reported VHs ther-
mal stability varied in a wide range [3,20,21]. Thermodynamic
stability, as a most reliable quantity characterizing protein
folding in solution, was not determined for VH domains by
the high-resolution method of di¡erential scanning calorime-
try. In this work, we applied a combination of calorimetric
and spectroscopic probes to the VH domain derived from the
anti-human ferritin monoclonal antibody F11 (mouse IgG2a/
U subclass) and provide here the ¢rst description of a func-
tional antibody domain that does not attain complete folding
under the physiological conditions and constitutes a partially
unfolded, molten globule-like state.
2. Materials and methods
2.1. DNA cloning procedures
A fragment encoding the VH domain was generated by PCR from
the gene scFv (single-chain Fv fragment)-F11 that encoded the VH-
linker-VL construct (single-chain antibody F11 [22]). The plasmid
pETscF11 was used together with the following PCR primers:
GGATCCCATATGCAGGTGCAGCTGAAGCAG (forward); GC-
CTGGCTCGAGTGAGGAGACTGTGAG (reverse). The resulting
PCR fragment was digested with the restriction enzymes NdeI and
XhoI and gel-puri¢ed for subsequent ligation into the T7 expression
vector pET-22b+ which includes a sequence for a C-terminal hexahis-
tidine tag immediately downstream of the XhoI site. The ligation
mixture was used to transform Escherichia coli XL1-Blue cells, and
the nucleotide sequence of the resulting construct obtained from a
single colony was con¢rmed by dideoxy sequencing.
2.2. Expression of VH domain
E. coli BL21(DE3) cells transformed with the pET22VH plasmid
were grown in 1 l of LB broth containing ampicillin (100 mg/l) at
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37‡C until the culture reached the middle of the log phase. Then,
isopropyl-L-D-thiogalactopyranoside was added to a ¢nal concentra-
tion of 20 WM and the bacterial cells were grown for an additional 4 h
at 37‡C. The cells were harvested by centrifugation at 3000Ug for 10
min, suspended in 60^80 ml of 50 mM Tris^HCl, pH 8.0, containing
0.15 M NaCl and 1 mM phenylmethanesulfonyl £uoride (PMSF),
centrifuged as above and washed twice with the same bu¡er. The cells
were resuspended in 60^80 ml of the above bu¡er, disintegrated by
sonication and centrifuged at 15 000Ug for 30 min. The sediment of
inclusion bodies typically contained VH domain with a purity of 30^
40%.
2.3. Puri¢cation and refolding procedures
The pellet of inclusion bodies containing the VH domain was solu-
bilized with 6 M guanidine hydrochloride (GdnHCl) in bu¡er A
(0.05 M sodium borate, pH 8.5) for 1 h at room temperature. After
centrifugation for 45 min at 40 000Ug, the supernatant was dialyzed
against 6 M urea in bu¡er A containing 1 mM PMSF, then centri-
fuged to remove precipitated material and loaded on a Ni-NTA-Seph-
arose column equilibrated with bu¡er A without imidazole. The col-
umn was washed with 10 volumes of the bu¡er, and the bound VH
domain was eluted with bu¡er A containing 250 mM imidazole. The
fractions containing the VH domain were pooled and dialyzed against
bu¡er A, then loaded on the DEAE-cellulose column equilibrated
with bu¡er A. Under these conditions, the VH domain did not bind
to the column, in contrast to residual contaminating proteins. To
refold the puri¢ed VH domain, the £owthrough fraction collected
after ion exchange chromatography was dialyzed against 3 M, then
1 M urea in bu¡er A, with centrifugation after dialyses performed as
above. Finally, the protein was dialyzed against 0.05 M sodium borate
bu¡er, pH 8.5, centrifuged, and used for further experiments. Typi-
cally, the yield of refolded and puri¢ed VH domain was 20^40 mg
from 1 l of the cell culture. Puri¢cation of the monoclonal anti-ferritin
antibody F11 [23,24] and human spleen ferritin [23,25] was described
previously. The VL domain of the F11 antibody was expressed in
inclusion bodies and puri¢ed according to the previously reported
procedure [26].
2.4. Determination of antigen-binding a⁄nity
The antigen-binding a⁄nity was determined in a competition en-
zyme immunoassay as described earlier [22]. In the assay procedure,
binding of the biotinylated antibody F11 to immobilized human
spleen ferritin was quanti¢ed in the presence of variable concentra-
tions of the VH domain or, alternatively, the VL domain or parent
F11 antibody, as a competitor. The assay was performed at room
temperature in triplicates. Variations in the Ka determination were
within 25%.
2.5. Fluorescence measurements
Fluorescence spectra of the proteins and protein^8-anilino-1-naph-
thalene sulfonic acid (ANS) complexes were recorded at room temper-
ature with a protein concentration of 0.05 mg/ml in a 1 cm path
length cuvette on a SFL-1211 £uorometer (Solar, Belarus) as we pre-
viously described in detail [27]. The protein tryptophan £uorescence
was excited at 295 nm, and the ANS £uorescence was excited at 360
nm. The ANS to protein molar ratios were equal to 10 and 120 for the
VH domain and parent F11 antibody, respectively.
2.6. Circular dichroism (CD)
Far-UV CD spectra were recorded on a J-20 spectropolarimeter
(Jasco, Japan) at a protein concentration of 0.3^0.6 mg/ml as previ-
ously described [26]. Mean residue ellipticities were calculated using
the value of 115 for the mean residue weight.
2.7. Di¡erential scanning calorimetry
Measurements were performed with a DASM-4 scanning calorim-
eter (Biopribor, Pushchino, Russia) in the temperature range 10^
100‡C at a scan speed of 60 K/h as described previously [26]. The
protein concentrations ranged between 0.5 and 1.5 mg/ml. Heat ca-
pacity curves were analyzed using software TERMCALC and
WSCAL supplied by the DASM-4 manufacturer.
2.8. Size-exclusion chromatography
The protein oligomerization state was determined by size-exclusion
chromatography at room temperature using a BIO-SIL SEC 250-5
column (0.78U30 cm) and Pharmacia high-performance liquid chro-
matography (HPLC) system, which was calibrated with molecular
mass standards (thyroglobulin, 650 kDa; IgG, 150 kDa; ovalbumin,
45 kDa; myoglobin, 17.8 kDa; B12, 1.34 kDa). The sample volume
was 0.1 ml, and the protein concentration was 1 mg/ml.
2.9. Quantitative assay for disul¢des and free thiols
The number of disul¢des in the puri¢ed and refolded VH domain
was determined by the method of Thannhauser et al. [28] in a protein
solution containing 3 M guanidine thiocyanate, a denaturing agent
that does not interfere with the assay. Free thiols were assayed with
5,5P-dithio-bis(2-nitrobenzoic acid) as described by Ellman [29] both
in the presence and absence of the denaturant.
2.10. Other methods
SDS^PAGE was performed according to Laemmli [30] and stained
with Coomassie brilliant blue R-250. Concentrations of proteins were
determined from the absorption of a 0.1% solution in a 1 cm path
length cuvette at 280 nm. The absorption values of 1.62 for the F11
antibody, 1.15 for the VL, and 2.28 for the VH domains were calcu-
lated from the known amino acid sequences according to [31].
3. Results
3.1. Monomeric state and antigen-binding a⁄nity of the VH
domain
Quantitation of disul¢des and free thiols for the VH do-
main obtained by our refolding/puri¢cation procedure showed
that VH did not contain refolding conformers derived from
incorrect disul¢de bonding or formation of sulfur derivatives.
In four di¡erent preparations of VH, the number of disul¢des
was 0.97 þ 0.05, and no free thiols were detected, which is fully
Fig. 1. Size-exclusion HPLC of the VH domain on a BIO-SIL SEC
250-5 column (0.78U30 cm). Samples of VH were applied on the
column either immediately after refolding and concentrating proce-
dure (A), or after 4 days of storage at 2^4‡C (B). Elution bu¡er:
0.05 M borate, pH 8.5. Protein concentration: 0.6 mg/ml. Arrows
indicate elution time of the molecular mass standards that were as
follows: 650 kDa, thyroglobulin; 150 kDa, rabbit immunoglobulin
G; 45 kDa, ovalbumin; 17.8 kDa, myoglobin; 1.36, B12 vitamin.
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consistent with a single disul¢de bond present in the VH do-
main. Previously, a similar puri¢cation/refolding procedure
yielded correct disul¢de bonding for the VL domain and
VH-linker-VL construct (the scFv fragment) derived from
the same F11 antibody [22,26].
The predominantly monomeric state of the VH domain,
consistent with the previous data [1,32,33], was demonstrated
by size-exclusion chromatography (Fig. 1). We observed a
sharp and symmetric peak corresponding to an apparent Mr
of V15 kDa, as expected from the known amino acid se-
quence (13 991 Da) and SDS^PAGE data. After 4 days of
storage at 4‡C, a small amount (less than 10%) of soluble
higher oligomers with apparent Mr exceeding 200 kDa was
observed. Therefore, freshly prepared protein samples were
used for our physical and functional measurements to avoid
uncertainties resulting from any small fraction of oligomeric
VH.
The VH domain displayedV23 times lower ferritin-binding
a⁄nity (Fig. 2) than the parent full-length F11 antibody
(Ka = 4.0U107 M31 and 8.6U108 M31, respectively). This dif-
ference in the a⁄nity constants most probably re£ects the
contribution of the partner VL domain to generating the
high-a⁄nity antigen-binding site. The VL domain displayed
V45-fold decrease in binding a⁄nity versus the parent anti-
body F11 (Fig. 2), thus indicating a greater contribution of
the VH domain to the binding a⁄nity. A similar decrease in
the antigen-binding a⁄nity has previously been observed
when isolated VH domains were compared with their parent
full-length antibodies [1], and the same order of magnitude for
the a⁄nity constant has been obtained for a series of VH
domains [33]. Thus, the decrease in the binding a⁄nity of
our VH domain is not dramatic and allows reliably detectable
binding to the speci¢c antigen, human spleen ferritin. Our
a⁄nity measurements con¢rm the prediction that VH do-
mains may constitute minimal binding modules that are capa-
ble of speci¢cally recognizing antigens and can be used as
targeting moieties for engineered immunotoxins and other fu-
sions of biomedical signi¢cance. Given the reduction in a⁄n-
ity, not all of three hypervariable CDR loops in our VH
domain might be involved in binding of ferritin. It was re-
cently shown that the camel anti-carbonic anhydrase VH do-
main interacts with the antigen with nanomolar a⁄nity
through the surface-exposed third hypervariable loop without
involvement of the CDR1 and CDR2 loops [15].
3.2. CD
Far-UV CD spectrum of the VH domain (Fig. 3) demon-
strates a prominent band at 216 nm with a Vthree-fold in-
crease in negative ellipticity versus the native full-length anti-
body F11 or its isolated VL domain. This spectrum is also
distinct from that of denaturant-unfolded VH. A similar in-
crease of negative ellipticity in the far-UV region has been
observed at strongly acidic pH for partially unfolded states
of the mouse monoclonal antibodies and their Fab fragments
[34^36], as well as the isolated CH3 [37] and VL [38,39] do-
mains. Together, these data and our CD spectra indicate that
the anti-ferritin VH domain adopts a non-native secondary
conformation with a signi¢cant amount of a L-sheet structure
which is markedly distorted and resembles the structure of
immunoglobulins partially unfolded under strongly acidic
conditions.
3.3. Fluorescence spectroscopy
The intrinsic £uorescence spectrum of the VH domain (Fig.
4A) suggests a compact conformation with aromatic £uoro-
phores protected from quenching by solvent, as judged by the
emission maximum around 338 nm in the native protein and a
red shift to 352 nm observed after unfolding in the denatur-
ant. However, the VH domain is capable of binding to the
hydrophobic dye ANS (Fig. 4B). Binding of ANS represents a
generally acceptable probe for a partially unfolded tertiary
structure that allows the access to a protein hydrophobic
core [40,41]. Neither the denaturant-unfolded VH domain
Fig. 2. Antigen-binding a⁄nity of VH domain, VL domain and
full-length parent antibody F11 determined by competitive ELISA.
The Ka values were obtained from double-reciprocal plots. A and
A0 ^ absorbance at 492 nm, respectively in the presence or absence
of a competitor.
Fig. 3. Far-UV CD spectra of the VH domain, parent full-length
antibody F11 and its VL domain.
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nor the native F11 antibody and its VL domain bind the
hydrophobic dye. Noteworthy is that a partially structured
state obtained at pH 2 for the parent F11 antibody [26] and
for the VL domain (Fig. 4B) displayed pronounced binding of
ANS similar to that observed for the VH domain at neutral
pH. Taken together, the £uorescence spectroscopy data are
indicative of the partially unfolded tertiary conformation of
the VH domain with signi¢cantly destabilized tertiary inter-
actions. The fact that the isolated VL domain does not bind
ANS at neutral pH demonstrates that the high ANS-binding
propensity of our VH domain cannot be attributed to solvent-
exposed hydrophobic residues which are buried in full-length
antibodies within the domain interfaces.
3.4. Thermodynamic stability
Di¡erential scanning calorimetry revealed a low-coopera-
tive and irreversible thermal transition of the VH domain.
When compared to the isolated anti-ferritin VL domain,
which is completely folded [26], the tertiary structure of the
VH domain is quite distinct (Fig. 5). First, the VH domain
does not display the sharp heat absorption peak as the VL
domain does. Although the di¡erence in midpoint transition
temperature, Tm, determined for the two proteins is rather
small (57‡C for VH and 60.5‡C for VL), the transition en-
thalpy for the VH domain is dramatically low (V0.15 cal/g
versus 3.9 cal/g). Second, the heat capacity of the VH domain
in the pre-transition region (below 50‡C) is markedly higher,
suggesting partial exposure of hydrophobic residues, consis-
tent with the ANS-binding data. However, the heat capacity
does not reach the value characteristic for fully unfolded VH,
as demonstrated by a comparison of the ¢rst and second
calorimetric scans. This comparison indicates the presence in
the VH domain of a tertiary structure with a fraction of hy-
drophobic amino acids involved in hydrophobic packing.
Thus, our calorimetric study strongly suggests that the VH
domain possesses a compact tertiary conformation that is,
however, signi¢cantly destabilized and constitutes a partially
structured state.
4. Discussion
In this work, we demonstrate that the functional VH do-
main of the mouse anti-ferritin antibody F11 does not attain
complete folding under physiological conditions. Instead, it
adopts a partially structured state with a signi¢cant amount
of a distorted secondary structure and compact yet greatly
destabilized tertiary structure. These data provide the ¢rst
description for a functional antibody domain that meets all
the criteria of a partially structured state highly populated
under physiological conditions. In this regard, our VH do-
main can be attributed to the recently described family of
Fig. 4. A: Intrinsic £uorescence spectra of the VH domain. B:
Fluorescence spectra of a hydrophobic probe, ANS, in the presence
of the following proteins: 1, ‘native’ VH domain; 2, unfolded VH
domain (6 M GdnHCl); 3, native parent antibody F11; 4, native
VL domain; 5, partially unfolded VL domain (pH 2).
Fig. 5. Di¡erential scanning calorimetry of the VH domain in com-
parison with the VL domain under the optimized solvent conditions.
Bu¡ers: 0.05 M sodium phosphate, pH 7.0 for VL and 0.05 M so-
dium borate, pH 8.5 for the VH domain.
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‘natively unfolded’ proteins that adopt a partially structured
conformation under physiological conditions [42,43]. For
some of these proteins, intrinsically disordered conformations
adopt a fully folded structure upon binding to their biological
target [43]. Our results therefore rise the question as to
whether the F11-reactive epitope of ferritin can be involved
in inducing complete folding of the antibody variable domain;
this question, however, cannot be resolved within the scope of
the current study.
Given the typical immunoglobulin fold previously reported
for the recombinant VH domains [6,33], the structural origin
of incomplete folding shown for our VH domain cannot be
attributed solely to stabilizing trans and cis interactions be-
tween the VH and partner VL and CH1 domains that are
present in Fab fragments and naturally occurring antibodies
but lacking in the isolated VHs. It seems more reasonable to
suggest that a unique sequence of CDR loops in our anti-
ferritin VH domain might constitute a major determinant of
its partially unfolded conformation. This suggestion is consis-
tent with the previously reported critical contribution of CDR
loops to folding and stability of variable domains [16^19]. An
alternative explanation that would involve a strongly destabi-
lizing contribution of the C-terminal hexahistidine tag seems
unlikely because a large number of engineered proteins are
known to tolerate this tag without major conformational al-
terations. Furthermore, the VL domain of the same F11 anti-
body did reach complete folding and functionality with the C-
terminal six histidines [26]. To provide direct evidence for a
critical contribution of the CDR loops into the partially un-
folded conformation of our VH, thermodynamic stability
studies of engineered VHs with variable CDR loops grafted
into the same framework region are required.
Previously, we demonstrated that the isolated VL domain
of the F11 antibody is functional and does reach complete
folding, in contrast to the functional VH-linker-VL fusion
protein (scFv fragment F11) that comprises the two domains
trapped in a partially unfolded state [22,26]. Plu«ckthun and
co-workers provided convincing evidence that premature in-
teractions between partially structured VH and VL domains
within an scFv fragment might result in a kinetic trap along
the folding pathway [44,45]. Given these data, a partially un-
folded conformation for both VL and VH domains within the
scFv fragment F11 under physiological conditions can be at-
tributed to premature interactions that the partially structured
VH domain establishes with the partner VL domain before
the latter attains complete folding. Additional studies are
needed in order to establish whether the combination of func-
tionality and partially folded conformation is unique for our
VH domain or it can be also observed for other variable
domains.
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